Boron LePore Glucophage peer-to-peer meetings increase physician scripts 20%, BLP says.
BORON LEPORE GLUCOPHAGE MEETINGS PRODUCE 20% MORE SCRIPTS from physicians who attend the events, Boron LePore Chief Operating Officer Gregory Boron told the Hambrecht & Quist healthcare conference Jan. 15. Return-on-investment analyses by Bristol-Myers Squibb demonstrated "that as a direct result of doctors attending our dinner meetings, the doctor is writing almost 20% more Glucophage [prescriptions] after leaving the meeting," Boron said. The meetings were conducted after the launch of Warner-Lambert's competing oral anti-diabetic Rezulin.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth